Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases …
J Stemler, SC Mellinghoff… - Journal of …, 2023 - academic.oup.com
Patients with haematological malignancies (HM) are at high risk of developing invasive
fungal disease (IFD) with high morbidity and attributable mortality. We reviewed data …
fungal disease (IFD) with high morbidity and attributable mortality. We reviewed data …
Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus …
J Stemler, N de Jonge, N Skoetz, J Sinkó… - The Lancet …, 2022 - thelancet.com
On the basis of improved overall survival, treatment guidelines strongly recommend
antifungal prophylaxis during remission induction chemotherapy for patients with acute …
antifungal prophylaxis during remission induction chemotherapy for patients with acute …
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose …
A Bazinet, F Darbaniyan, E Jabbour… - The Lancet …, 2022 - thelancet.com
Background Therapies beyond hypomethylating agents such as azacitidine are needed in
high-risk myelodysplastic syndromes. Venetoclax is an orally bioavailable small molecule …
high-risk myelodysplastic syndromes. Venetoclax is an orally bioavailable small molecule …
Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs
RJ Brüggemann, R Verheggen, E Boerrigter… - The Lancet …, 2022 - thelancet.com
Over the past 10 years, the number of targeted therapies for haematological malignancies
has substantially increased, and many new drugs have entered the market. Many of these …
has substantially increased, and many new drugs have entered the market. Many of these …
Venetoclax with Hypomethylating agents in newly diagnosed Acute myeloid leukemia: a systematic review and Meta-analysis of Survival Data from Real-World …
A Ucciero, F Pagnoni, L Scotti, A Pisterna… - Cancers, 2023 - mdpi.com
Simple Summary The association of venetoclax (VEN) with hypomethylating agents (HMAs)
such as azacitidine (AZA) and decitabine (DECI) significantly improved the outcome of …
such as azacitidine (AZA) and decitabine (DECI) significantly improved the outcome of …
Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US
Background Treatment with venetoclax+ hypomethylating agents (HMAs) is standard-of-care
for newly diagnosed (ND) patients with acute myeloid leukemia (AML) aged≥ 75 years, or …
for newly diagnosed (ND) patients with acute myeloid leukemia (AML) aged≥ 75 years, or …
Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted …
CR Rausch, AJ DiPippo, Y Jiang… - Clinical Infectious …, 2022 - academic.oup.com
Background Multiple factors influence the choice of primary antifungal prophylaxis (PAP) in
patients with acute myeloid leukemia (AML) undergoing remission induction chemotherapy …
patients with acute myeloid leukemia (AML) undergoing remission induction chemotherapy …
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax
EC Chen, Y Liu, CE Harris, ES Winer… - Leukemia & …, 2022 - Taylor & Francis
Antifungal prophylaxis (AFP) is recommended for acute myeloid leukemia (AML) patients
receiving the combination of venetoclax (VEN) and a hypomethylating agent (HMA), but the …
receiving the combination of venetoclax (VEN) and a hypomethylating agent (HMA), but the …
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
M Fleischmann, S Scholl, JJ Frietsch… - Journal of Cancer …, 2022 - Springer
Background Diagnosis of acute myeloid leukemia (AML) is associated with poor outcome in
elderly and unfit patients. Recently, approval of the BCL-2 inhibitor venetoclax (VEN) in …
elderly and unfit patients. Recently, approval of the BCL-2 inhibitor venetoclax (VEN) in …
[HTML][HTML] Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
Venetoclax+ azacitidine is the standard of care for newly-diagnosed patients with acute
myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to …
myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to …